Hims & Hers Growth Story Has A Lot To Prove In 2026

Impact · against what's priced in

HIMS faces immediate valuation pressure as the growth thesis shifts from GLP-1 momentum to unproven long-term vectors. The combination of lowered FY25 guidance and margin contraction indicates a fundamental deceleration that outweighs management's 2030 aspirations.

HIMS−0.70

No priced-in read yet

In context

The stock is under pressure due to lowered FY25 guidance, sequential revenue deceleration, and margin contraction, alongside fading momentum in the critical compounded GLP-1 segment.

Read from the article alone

• guidance
• healthcare
• HIMS
• compounded drugs
• glp 1
• revenue deceleration
• telehealth
• weight loss drugs

Search tags